David T. Rubin

David T. Rubin is an American Gastroenterologist and educator. He is the Joseph B. Kirsner Professor of Medicine and professor of pathology at the University of Chicago, where he is also the chief of the Section of Gastroenterology, Hepatology and Nutrition.^[1] He also serves as the director of the Inflammatory Bowel Disease Center at the University of Chicago. He is also an associate faculty member at the MacLean Center for Clinical Medical Ethics, associate investigator at the University of Chicago Comprehensive Cancer Center and a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics.

David T. Rubin obtained his Doctor of Medicine degree with honors at the University of Chicago Pritzker School of Medicine. He went on to complete his internship, residency, and fellowship at the University of Chicago where he served as Chief Resident and Chief Fellow.^[2] He also completed a fellowship in Clinical Medical Ethics at the MacLean Center for Clinical Medical Ethics and a leadership development course at the Harvard T.H. Chan School of Public Health.

David T. Rubin specializes in the treatment and assessment of inflammatory bowel diseases (Crohn's disease and ulcerative colitis).^[1]

Dr. Rubin performs scientific research related to outcomes in inflammatory bowel diseases with particular interest in the prevention of cancer associated with these diseases and strategies to modify the disease course and control inflammation. He is involved in the design and execution of clinical trials for new therapies in inflammatory bowel diseases.^[3]

Dr. Rubin is a Fellow of the American Gastroenterological Association (AGAF), the American College of Gastroenterology (FACG), the American Society for Gastrointestinal Endoscopy (FASGE), the American College of Physicians (FACP), and the Royal College of Physicians in Edinburgh (FRCP (Edinburgh)).^[2] Dr. Rubin is a Co-Founder (with Dr. Marla Dubinsky) of Cornerstones Health, Inc, a non-profit medical education organization. He is the immediate past chair of the National Scientific Advisory Committee of Crohn's & Colitis Foundation and Chair of the International Organization for the Study of IBD.

Dr. Rubin’s research is focused on disease modification in IBD including clinical trial designs, novel measures of inflammation and prevention of adverse outcomes, and quality of life in IBD. He has twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), and in 2020, Dr. Rubin received the Sherman Prize for Excellence in Crohn’s and Colitis. In 2023, he received both the UChicago Michael Reese Lectureship Award (for outstanding faculty who have developed novel teaching and clinical research that advances healthcare) and the distinguished UChicago Arthur H. Rubenstein Mentorship in Academic Medicine Award. Dr. Rubin is currently a senior editor of the 12th edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author on >500 articles on management of IBD, including the 2025 ACG Guidelines for ulcerative colitis.^[4]

Dr. Rubin is the editor of Curbside Consultation in IBD: 49 Clinical Questions, third edition and an editor of Sleisenger and Fordtran's Gastrointestinal and Liver Disease, twelfth edition. He is an associate editor of the journals of Intestinal Research, Inflammatory Bowel Diseases and Gastroenterology & Hepatology, and co-editor of the ACG Education Universe.

His latest publications can be found here.

1. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. Am J Gastroenterol. 2025 Jun 3;120(6):1187-1224.
2. Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease. Christensen B, Gibson P, Micic D, Colman RJ, Goeppinger S, Kassim O, Yarur A, Weber C, Cohen RD, Rubin DT. Clin Gastroenterol Hepatol. 2019;17(3):486-493.
3. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, Hart J, Rubin DT.  Clin Gastroenterol Hepatol. 2017;5:1557-64.
4. The Crohn's and Colitis Foundation of America Survey of Inflammatory Bowel Disease Patient Healthcare Access.  Rubin DT, Feld LD, Goeppinger S, Kim S, Margolese JM, Rosh J, Rubin M, Rodriquez DM, Wingate L.  Inflamm Bowel Dis.  2017;23:224-32.
5. Using a Treat-to-Target Management Strategy to Improve the Doctor-Patient Relationship in Inflammatory Bowel Disease. Rubin DT, Krugliak Cleveland N.  Am J Gastroenterol. 2015;110:1252-6.
6. Ethical Consideration for Clinical Trials in Inflammatory Bowel Disease.  Rubin DT, Becker S, Siegler M.  Gastroenterol Hepatol. 2014;10:37-41.
7. Inflammation is an Independent Risk Factor for Colonic Neoplasia in Patients with Ulcerative Colitis: A Case-Control Study. Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR.  Clin Gastroenterol Hepatol.  2013;11:1601-8.

• Rubin Lab Website
• Twitter
• Section of Gastroenterology, Hepatology, and Nutrition at The University of Chicago